ACELYRIN INC. - COMMON STOCK

ACELYRIN Adopts Limited-Duration Stockholder Rights Plan

13 Mar 2025 06:00:00 By Nasdaq GlobeNewswire

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

04 Mar 2025 08:01:00 By Nasdaq GlobeNewswire

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

04 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences

20 Feb 2025 20:00:01 By Nasdaq GlobeNewswire

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

06 Feb 2025 15:15:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease

06 Jan 2025 15:00:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab

02 Jan 2025 19:00:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis

10 Dec 2024 15:30:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights

13 Nov 2024 15:00:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024

06 Nov 2024 15:00:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease

16 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024

19 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery

10 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. to Participate in Upcoming Investor Conferences

22 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results

13 Aug 2024 15:00:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024

06 Aug 2024 15:30:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024

05 Jun 2024 06:00:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024

29 May 2024 06:00:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones

09 May 2024 07:01:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Announces Leadership Transition

09 May 2024 07:00:00 By Nasdaq GlobeNewswire